Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 223

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Is nedocromil sodium effective treatment for asthma?

Open access
O'Byrne, PM, Cook, D·1993·European Respiratory Journal

Abstract

In the past decade, the Lreaune nt of usLhma has changed. This evolution occurred with the realization that prevention of regular asthma symptoms is preferable to treatme nt of asthmatic symptoms when they develop. Thi s unders tanding is reflected in the consensus reports on asthma management , which have rece ntly been publi shed in several countries ll-41 . These reports agree that the main aim of management is to keep asthmatic patients functioning as c lose to normal. f()r as muc h of the rime, as possible. With this in mind, the currently available drugs to treat asthma, for practical purposes, fall into two classes: those which are most useful to treat symptoms when they develop (such as P 2 -agonists or theophylline), and those which are most useful in preventing regular sympLOms and exaccrbat ions of asthma from occ uring (suc h as inhaled corticos te roids or cromoglycate). Whilst this division is somewhat artificial, (for example, inhaled P2-agonists are very useful for preventing exerc iseinduced bronc hoconsLriction) . the distinction between these c lasses of drugs IHL~ practical importance, as inhal ed corticosteroids or c rorn-oglycate arc now recomme nded as the most appropriate regular maintenance treatment for asthmatic patients witb anything o ther than infrequent symptoms [1-4]. A recent addition to the physicians therapeutic armament for asthma treatment is nedocromil sodium, which was originally developed as an agent which would inhibit the release of mediators from inflammatory cells present in the airways of all (even mild, stable) asthmatics. The drug was developed as an extension of cromolyn, which was thought at the time to have similar pharmacological properties. It was hoped that nedocromil would have significant therapeutic advantages, but would retain the low side-effect profile of cromolyn. Nedocromil has been extensively studied in asthma, and the results of all known published and unpublished, placebo-controlled, double-blind, randomized clinical trials have been incorporated into a metaanalysis by EowARDS and STEVENS [5]. These authors are associated with the company which has developed and marketed nedocromil and, thereby, have access to all available clinical trials, including unpublished data,

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/09031936.93.06010005

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 223

Metadata

Authors
O'Byrne, P., & Cook, D.
Venue
European Respiratory Journal
Published
1993-01-01
Volume
6
Issue
1
Pages
5-6
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W1891990519
Cited by
223
References
2
FWCI
0.42
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Is nedocromil sodium effective treatment for asthma? https://app.cochat.ai/papers/10.1183/09031936.93.06010005
The paper
O'Byrne, P., & Cook, D. (1993). Is nedocromil sodium effective treatment for asthma? European Respiratory Journal. https://doi.org/10.1183/09031936.93.06010005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.